Johnson & Johnson and BioMarin Pharmaceutical Inc.: SG&A Spending Patterns Compared

SG&A Spending: Johnson & Johnson vs. BioMarin

__timestampBioMarin Pharmaceutical Inc.Johnson & Johnson
Wednesday, January 1, 201430215600021954000000
Thursday, January 1, 201540227100021203000000
Friday, January 1, 201647659300019945000000
Sunday, January 1, 201755433600021420000000
Monday, January 1, 201860435300022540000000
Tuesday, January 1, 201968092400022178000000
Wednesday, January 1, 202073766900022084000000
Friday, January 1, 202175937500020118000000
Saturday, January 1, 202285400900019046000000
Sunday, January 1, 202393730000020112000000
Monday, January 1, 2024100902500021969000000
Loading chart...

Cracking the code

SG&A Spending Patterns: A Tale of Two Giants

In the world of pharmaceuticals, understanding spending patterns can reveal much about a company's strategic priorities. Over the past decade, Johnson & Johnson and BioMarin Pharmaceutical Inc. have showcased contrasting approaches in their Selling, General, and Administrative (SG&A) expenses.

From 2014 to 2023, Johnson & Johnson consistently allocated a significant portion of its budget to SG&A, with expenses peaking at approximately $22 billion in 2018. This reflects a robust commitment to maintaining its market presence and operational efficiency. In contrast, BioMarin's SG&A expenses, while much smaller, have shown a steady increase, growing by over 200% from 2014 to 2023. This suggests a strategic expansion and investment in growth initiatives.

These spending patterns highlight the different scales and strategies of these industry leaders, offering insights into their operational priorities and market positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025